Lilly's Kisunla Clears Crucial Hurdle for Canadian Reimbursement

TORONTO, ON – November 06, 2026 — The Canadian healthcare landscape is bracing for a profound strategic shift in neurodegenerative care following a landmark decision by Canada's Drug Agency (CDA-AMC). Eli Lilly Canada Inc. announced today that the agency has issued a positive recommendation to publicly reimburse Kisunla (donanemab), an amyloid-targeting therapy for eligible adults diagnosed with early symptomatic Alzheimer's disease.

The recommendation positions Canada among the first internationally recognized health technology assessment bodies to back public funding for the drug, which received Health Canada authorization in April 2026. Administered as an intravenous infusion once every four weeks, Kisunla is now the second disease-modifying treatment to receive a positive reimbursement nod in the country, following Eisai and Biogen's lecanemab.

Yet, while the CDA-AMC's green light is a critical milestone for Eli Lilly and the broader pharmaceutical sector, it represents only the first step in a complex, multi-layered journey toward actual patient access. For healthcare policymakers, provincial administrators, and industry analysts, the introduction of disease-modifying Alzheimer's drugs signals not just a medical breakthrough, but an impending logistical and economic stress test for Canada's publicly funded health systems.

The Promise and Complexity of Disease Modification

For decades, Alzheimer's treatment has been largely relegated to managing symptoms. The arrival of therapies like Kisunla represents a fundamental paradigm shift toward altering the underlying pathology of the disease. The drug works by clearing amyloid plaques in the brain, a key hallmark of Alzheimer's, thereby slowing cognitive and functional decline.

"Kisunla represents an important step in changing the way we treat dementia. It is now the second treatment approved and recommended in Canada that can slow down Alzheimer's disease," said Dr. Alexandre Henri-Bhargava, a behavioural neurologist and clinical researcher specializing in Alzheimer's and related conditions. "Although the administration of drugs like Kisunla is complex, and only a minority of patients with a diagnosis of Alzheimer's disease are eligible, these drugs offer hope and meaningful slowing down of the disease for the first time."

However, this clinical promise is bound by stringent eligibility criteria and significant safety considerations. The CDA-AMC's recommendation restricts coverage to adults with mild cognitive impairment or mild dementia who have confirmed amyloid pathology. Crucially, patients must be apolipoprotein E epsilon 4 (APOE4) non-carriers or heterozygotes. Those who are homozygous for the APOE4 gene variant are excluded due to a heightened risk of severe side effects.

The primary safety concern surrounding Kisunla is Amyloid-Related Imaging Abnormalities (ARIA), which can manifest as brain swelling (ARIA-E) or microhemorrhages (ARIA-H). Data from the Phase 3 TRAILBLAZER-ALZ 2 trial demonstrated that while donanemab reduced clinical decline by up to 40% in earlier stages of the disease, it also resulted in ARIA-E in nearly a quarter of participants. Managing this risk requires an updated dosing schedule and rigorous, ongoing MRI monitoring—a requirement that introduces substantial complexity to the patient care pathway.

The Infrastructure Gap: From Recommendation to Access

The gap between federal approval, agency recommendation, and actual clinical delivery is where the strategic challenge truly lies. The CDA-AMC recommendation now triggers price negotiations through the pan-Canadian Pharmaceutical Alliance (pCPA). These negotiations typically span 12 to 18 months, after which individual provinces and territories must independently decide whether to list the drug on their public formularies.

Industry observers note that provincial adoption is rarely uniform. For instance, the rollout of the preceding drug, lecanemab, faced headwinds when Quebec's health technology assessment body recommended against provincial coverage late last year.

"We applaud the positive recommendation from Canada's Drug Agency (CDA-AMC) for Kisunla, which recognizes the importance of giving eligible patients with early symptomatic Alzheimer's disease a treatment option at a time when intervention matters," stated Mathilde Merlet, President and General Manager of Lilly Canada. "Lilly remains committed to working with governments and the broader healthcare ecosystem to accelerate access to Kisunla."

Accelerating that access, however, requires a massive overhaul of existing medical infrastructure. To identify eligible patients, clinics must have access to specialized biomarker testing, such as amyloid PET scans or cerebrospinal fluid (CSF) analysis, along with APOE4 genetic testing. Currently, PET imaging capacity is heavily concentrated in major Canadian urban centers, creating the potential for severe geographic inequities in access.

Furthermore, the mandatory MRI monitoring for ARIA will place additional strain on already backlogged provincial radiology departments. As Dr. Henri-Bhargava noted, healthcare organizations must be incentivized to "provide organized systems of care for families with Alzheimer's and related disorders. It is time for these conditions to receive the same priority from our healthcare system as other serious conditions like cancer and heart disease."

"Treatments that can slow progression of Alzheimer's disease are incredibly meaningful as they preserve time and independence," added Christina Scicluna, CEO of the Alzheimer Society of Canada. "Today's recommendation brings new treatment options one step closer to Canadians, creating hope for those who are affected by Alzheimer's disease while also underscoring the importance of all Canadians having access to a timely diagnosis."

The Economic Crossroads of Dementia Care

The strategic shift brought on by Kisunla also forces a reckoning with the macro-economic realities of dementia care. Alzheimer's disease accounts for 60-80% of all dementia diagnoses. With more than 770,000 Canadians estimated to be living with dementia in 2025—a figure projected to soar to 1.7 million by 2050—the economic burden is staggering, currently estimated at $40 billion annually.

Pharmaceutical interventions offer a potential offset to these long-term care costs by preserving patient independence, but the upfront price tag is steep. Prior to public coverage, Kisunla's list price was estimated at roughly $47,000 to $51,000 per patient for the first year of treatment. Consequently, the CDA-AMC's recommendation is strictly conditional upon Eli Lilly providing a significant price reduction to ensure cost-effectiveness for public drug plans.

Health economists point out that Canada's cautious approach mirrors international apprehension. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) initially rejected both lecanemab and donanemab due to cost-effectiveness concerns and ARIA risks, though both are currently under reconsideration following manufacturer appeals. Similarly, the European Medicines Agency initially refused marketing authorization before reversing its decision late last year.

The challenge for provincial health ministries will be balancing the immediate, high acquisition and administrative costs of intravenous monoclonal antibodies against the theoretical long-term savings of delayed institutionalization for dementia patients.

"The Fédération québécoise des Sociétés Alzheimer welcomes this recommendation, which represents an important step forward in access to new therapeutic options," said Sylvie Grenier, Executive Director of the Fédération québécoise des Sociétés Alzheimer. "It is essential that these scientific advances translate into equitable, safe access, accompanied by appropriate clinical follow-up, for eligible individuals. This development also underscores the importance of continuing to invest in research, early diagnosis, and support for those affected and their loved ones."

As Eli Lilly enters the pCPA negotiation phase, the broader healthcare sector will be watching closely. The successful integration of Kisunla into the Canadian market will require more than just a pricing agreement; it will demand a strategic modernization of diagnostic pathways, imaging capacity, and specialized clinical resources, setting a precedent for the wave of neurodegenerative therapies currently advancing through the global pipeline.